JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Apellis Pharmaceuticals Inc

Closed

SectorHealthcare

23.17 -0.64

Overview

Share price change

24h

Current

Min

22.67

Max

23.41

Key metrics

By Trading Economics

Income

258M

216M

Sales

280M

459M

P/E

Sector Avg

63.417

84.243

EPS

1.67

Profit margin

47.04

Employees

705

EBITDA

258M

228M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+37.22% upside

Dividends

By Dow Jones

Next Earnings

27 Feb 2026

Market Stats

By TradingEconomics

Market Cap

-872M

2.9B

Previous open

23.81

Previous close

23.17

News Sentiment

By Acuity

50%

50%

152 / 352 Healthcare

Apellis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Feb 2026, 00:00 UTC

Hot Stocks

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 Feb 2026, 22:55 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 Feb 2026, 21:44 UTC

Earnings

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 Feb 2026, 21:39 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 Feb 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 Feb 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 Feb 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 Feb 2026, 23:45 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 Feb 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 Feb 2026, 22:59 UTC

Acquisitions, Mergers, Takeovers

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 Feb 2026, 22:30 UTC

Earnings

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 Feb 2026, 22:30 UTC

Earnings

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 Feb 2026, 22:21 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 Feb 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 Feb 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 Feb 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4 Feb 2026, 21:53 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 Feb 2026, 21:51 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 Feb 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Feb 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

4 Feb 2026, 21:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

4 Feb 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Feb 2026, 21:45 UTC

Earnings

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 Feb 2026, 21:44 UTC

Earnings

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 Feb 2026, 21:43 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 Feb 2026, 21:41 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 Feb 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 Feb 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 Feb 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 Feb 2026, 21:30 UTC

Earnings

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

37.22% upside

12 Months Forecast

Average 32 USD  37.22%

High 48 USD

Low 19 USD

Based on 16 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

10

Buy

6

Hold

0

Sell

Sentiment

By Acuity

152 / 352 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat